Protagonist Therapeutics ( PTGX ) Reports Q3 Loss, Lags Revenue Estimates

Zacks Commentary
2025.11.07 00:34

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -5.08% and -52.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Zacks Commentary The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer